Targeting non-malignant disorders with tyrosine kinase inhibitors

Receptor and non-receptor tyrosine kinases are involved in multiple proliferative signalling pathways. Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved, revolutionized the treatment of chronic myelogenous leukaemia, and other TKIs with different spectra of kinase inhibition are used to treat renal cell carcinoma, non-small-cell lung cancer and colon cancer. Studies also support the potential use of TKIs as anti-proliferative agents in non-malignant disorders such as cardiac hypertrophy, and in benign-proliferative disorders including pulmonary hypertension, lung fibrosis, rheumatoid disorders, atherosclerosis, in-stent restenosis and glomerulonephritis. In this Review, we provide an overview of the most recent developments — both experimental as well as clinical — regarding the therapeutic potential of TKIs in non-malignant disorders.

[1]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[2]  D. Matei,et al.  Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum‐resistant ovarian cancer and primary peritoneal carcinomatosis , 2008, Cancer.

[3]  F. Breedveld,et al.  Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial , 2009, Annals of the rheumatic diseases.

[4]  N. Voelkel,et al.  Microsatellite Instability of Endothelial Cell Growth and Apoptosis Genes Within Plexiform Lesions in Primary Pulmonary Hypertension , 2001, Circulation research.

[5]  B. Kahan,et al.  Janus kinase 3: a novel target for selective transplant immunosupression , 2004, Expert opinion on therapeutic targets.

[6]  E. Olapade-Olaopa,et al.  Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer , 1999, British Journal of Cancer.

[7]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[8]  I. Beales,et al.  STIMULATION OF IL-8 PRODUCTION IN HUMAN GASTRIC EPITHELIAL CELLS BYHELICOBACTER PYLORI, IL-1β AND TNF-α REQUIRES TYROSINE KINASE ACTIVITY, BUT NOT PROTEIN KINASE C , 1997 .

[9]  F. Gao,et al.  IMATINIB MESYLATE INHIBITS FIBROGENESIS IN ASBESTOS-INDUCED INTERSTITIAL PNEUMONIA , 2007, Experimental lung research.

[10]  C. Sawyers,et al.  Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. , 2008, Blood.

[11]  R. Pazdur,et al.  Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate , 2008, Clinical Cancer Research.

[12]  S. Keyse,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Human & experimental toxicology.

[13]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[14]  M. Persico.  Placenta Growth Factor , 2001 .

[15]  D. Schroeder,et al.  Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. , 2010, American journal of respiratory and critical care medicine.

[16]  C. Betsholtz,et al.  Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. , 2002, The American journal of pathology.

[17]  N. Voelkel,et al.  Plexiform lesion in severe pulmonary hypertension: association with glomeruloid lesion. , 2001, The American journal of pathology.

[18]  S. Hubbard,et al.  Receptor tyrosine kinases: mechanisms of activation and signaling. , 2007, Current opinion in cell biology.

[19]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[20]  Y. Takeishi,et al.  Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch. , 2001, Journal of molecular and cellular cardiology.

[21]  R. Alexander,et al.  cAbl Tyrosine Kinase Mediates Reactive Oxygen Species– and Caveolin-Dependent AT1 Receptor Signaling in Vascular Smooth Muscle: Role in Vascular Hypertrophy , 2005, Circulation research.

[22]  C. Daniels,et al.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.

[23]  Fabian Kiessling,et al.  Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis , 2005, The Journal of experimental medicine.

[24]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[25]  G. Hansson,et al.  Immune mechanisms in atherosclerosis. , 1994, Coronary artery disease.

[26]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Golomb,et al.  Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. , 2004, Cardiovascular research.

[28]  Tony Hunter,et al.  Treatment for chronic myelogenous leukemia: the long road to imatinib. , 2007, The Journal of clinical investigation.

[29]  S. Nishikawa,et al.  Functional Blockade of Platelet-Derived Growth Factor Receptor-&bgr; but Not of Receptor-&agr; Prevents Vascular Smooth Muscle Cell Accumulation in Fibrous Cap Lesions in Apolipoprotein E–Deficient Mice , 2001, Circulation.

[30]  Inda,et al.  A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .

[31]  M. Nam,et al.  The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor. , 2000, The journal of gene medicine.

[32]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[33]  D. Ferry,et al.  A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response , 2007, Clinical Cancer Research.

[34]  S. Wulf,et al.  Amendment history : Corrigendum ( November 2013 ) An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic , 2018 .

[35]  L. Audoly,et al.  Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis , 2008, Arthritis research & therapy.

[36]  Richard G. W. Anderson,et al.  Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Controls Endocytosis and c-CBL-mediated Ubiquitination of the Platelet-derived Growth Factor Receptor β (PDGFRβ)* , 2005, Journal of Biological Chemistry.

[37]  X. Mariette,et al.  Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study , 2009, Arthritis research & therapy.

[38]  Michael Dick,et al.  “The whole is greater than the sum of the parts“ , 2010 .

[39]  E. Buchdunger,et al.  Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. , 1999, Circulation.

[40]  Richard G. W. Anderson,et al.  LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis , 2003, Science.

[41]  M. Halushka,et al.  Heart failure associated with sunitinib malate , 2008, Cancer.

[42]  L. Ellis,et al.  Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[44]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[45]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[46]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[47]  S. Srinivas,et al.  Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  S. Nikol,et al.  Recently patented applications of homologous cellular and extracellular agents as therapeutics or targets for the prevention of restenosis post-angioplasty. , 2006, Recent patents on cardiovascular drug discovery.

[49]  Richard G. W. Anderson,et al.  Platelet-derived Growth Factor Mediates Tyrosine Phosphorylation of the Cytoplasmic Domain of the Low Density Lipoprotein Receptor-related Protein in Caveolae* , 2002, The Journal of Biological Chemistry.

[50]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[51]  P. Sternberg,et al.  Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. , 2010, American journal of ophthalmology.

[52]  Yeon-Hee Park,et al.  BNP as a marker of the heart failure in the treatment of imatinib mesylate. , 2006, Cancer letters.

[53]  M. Mattson,et al.  Basic FGF attenuates amyloid β-peptide-induced oxidative stress, mitochondrial dysfunction, and impairment of Na+/K+-ATPase activity in hippocampal neurons , 1997, Brain Research.

[54]  J. Koziol,et al.  The role of alpha and beta platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[55]  D. Sin,et al.  Emerging drugs for the treatment of chronic obstructive pulmonary disease , 2006, Expert opinion on emerging drugs.

[56]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[57]  H. Boezen,et al.  The insulin-like growth factor 1 receptor in cancer: old focus, new future. , 2007, European journal of cancer.

[58]  H. Ghofrani,et al.  Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. , 2010, American journal of respiratory and critical care medicine.

[59]  Xiaoling Li,et al.  Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study , 2004, Modern Pathology.

[60]  S. Sleijfer,et al.  Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment , 2008, Nature Clinical Practice Oncology.

[61]  S. Gay,et al.  Is there a future for small molecule drugs in the treatment of rheumatic diseases? , 2008, Current opinion in rheumatology.

[62]  D. Gospodarowicz,et al.  Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[64]  G. Mcmahon,et al.  Weekly Dosing With the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor SU9518 Significantly Inhibits Arterial Stenosis , 2001, Circulation research.

[65]  S. Pullamsetti,et al.  Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling , 2008, Circulation.

[66]  A. Kojima,et al.  Mast cell chymase in pulmonary hypertension , 1999, Thorax.

[67]  N. Yorioka,et al.  PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation , 2006, Clinical and experimental immunology.

[68]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[69]  S. Schwartz,et al.  Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. , 1992, The Journal of clinical investigation.

[70]  J. Blay,et al.  Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. , 2007, European journal of cancer.

[71]  Gregory J. Chen,et al.  Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs. , 2006, Recent patents on cardiovascular drug discovery.

[72]  C. Strange,et al.  Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. , 1995, The Journal of rheumatology.

[73]  D. Hicklin,et al.  Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis. , 2006, Transplantation proceedings.

[74]  J. Cherrington,et al.  The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. , 2001, Blood.

[75]  F. Russo,et al.  EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. , 1998, Acta oncologica.

[76]  N. Voelkel,et al.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. , 2007, American journal of respiratory and critical care medicine.

[77]  I. Fishbein,et al.  Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-12951 , 2002, Transplantation.

[78]  D. Louis,et al.  Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. , 1996, Cancer research.

[79]  J. Bland,et al.  META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[80]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[81]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[82]  N. Voelkel,et al.  Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. , 2003, American journal of respiratory cell and molecular biology.

[83]  P. Serruys,et al.  Effect of an anti‐PDGF‐β‐receptor‐blocking antibody on restenosis in patients undergoing elective stent placement , 2003, International journal of cardiovascular interventions.

[84]  M. Humbert,et al.  Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. , 2009, The Journal of clinical investigation.

[85]  Donna Neuberg,et al.  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). , 2002, Cancer cell.

[86]  Erez M. Bublil,et al.  The EGF receptor family : spearheading a merger of signaling and therapeutics , 2007 .

[87]  C. Alpers,et al.  Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. , 1993, The Journal of clinical investigation.

[88]  M. Genovese,et al.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. , 2010, The New England journal of medicine.

[89]  P. Kaiser,et al.  Neovascular age-related macular degeneration: potential therapies. , 2008, Drugs.

[90]  B. Dahal,et al.  Role of epidermal growth factor inhibition in experimental pulmonary hypertension. , 2010, American journal of respiratory and critical care medicine.

[91]  P. Changelian,et al.  The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[92]  R. Atkins,et al.  PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. , 2001, Kidney international.

[93]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[94]  Matthew E. Ritchie,et al.  Myocardial Gene Expression Associated with Genetic Cardiac Hypertrophy in the Absence of Hypertension , 2008, Hypertension Research.

[95]  A. Clowes,et al.  PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon. , 1999, Circulation.

[96]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[97]  T. Sjöblom,et al.  Characterization of the chronic myelomonocytic leukemia associated TEL-PDGFβR fusion protein , 1999, Oncogene.

[98]  Richard G. W. Anderson,et al.  LRP1 Functions as an Atheroprotective Integrator of TGFβ and PDGF Signals in the Vascular Wall: Implications for Marfan Syndrome , 2007, PloS one.

[99]  P. Hirth,et al.  Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. , 2000, The Journal of clinical investigation.

[100]  I. Beales,et al.  Stimulation of IL-8 production in human gastric epithelial cells by Helicobacter pylori, IL-1beta and TNF-alpha requires tyrosine kinase activity, but not protein kinase C. , 1997, Cytokine.

[101]  E. Loukinova,et al.  Platelet-derived Growth Factor Receptor-β (PDGFR-β) Activation Promotes Its Association with the Low Density Lipoprotein Receptor-related Protein (LRP) , 2005, Journal of Biological Chemistry.

[102]  C. Heldin,et al.  Intimal Hyperplasia Recurs After Removal of PDGF-AB and -BB Inhibition in the Rat Carotid Artery Injury Model , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[103]  T. Hacker,et al.  Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. , 2007, The Journal of invasive cardiology.

[104]  Ulf Eriksson,et al.  PDGF-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerosis-prone flow patterns. , 2009, American journal of physiology. Heart and circulatory physiology.

[105]  T. L. Le Cras,et al.  Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[106]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[107]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[108]  F. Blackhall,et al.  Gefitinib for the treatment of non-small-cell lung cancer , 2010, Expert opinion on pharmacotherapy.

[109]  M. Humbert,et al.  Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension , 2007, European Respiratory Journal.

[110]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[111]  David Gruben,et al.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.

[112]  D. Borhani,et al.  Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. , 2006, Bioorganic & medicinal chemistry letters.

[113]  L. Schwartz,et al.  Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. , 2009, Clinical genitourinary cancer.

[114]  Khai Pang Leong,et al.  Tyrosine kinase inhibitors: a new approach for asthma. , 2004, Biochimica et biophysica acta.

[115]  Yuan Cheng,et al.  Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. , 2008, IDrugs : the investigational drugs journal.

[116]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[117]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[118]  J. Verweij,et al.  Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[119]  A. Hackshaw,et al.  A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC) , 2007 .

[120]  G. Giaccone,et al.  Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  M. Phillips,et al.  Antisense to Epidermal Growth Factor Receptor Prevents the Development of Left Ventricular Hypertrophy , 2003, Hypertension.

[122]  Ji-ping Wang,et al.  Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[123]  Richard Pazdur,et al.  Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib , 2008, Clinical Cancer Research.

[124]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[125]  T. Hunter,et al.  The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. , 1998, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[126]  N. Voelkel,et al.  Vascular endothelial growth factor in the lung. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[127]  T. Quinn,et al.  Cyclic mechanical stretch induces VEGF and FGF-2 expression in pulmonary vascular smooth muscle cells. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[128]  G. Remuzzi,et al.  Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. , 2006, Kidney international.

[129]  J. Wood,et al.  Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. , 2006, American journal of respiratory and critical care medicine.

[130]  F. Cavalli,et al.  A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. , 2003, Blood.

[131]  A. Bogers,et al.  Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease , 2000, The Journal of pathology.

[132]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[133]  S. Lepreux,et al.  The Effect of Imatinib (Glivec®) on Scleroderma and Normal Dermal Fibroblasts: A Preclinical Study , 2008, Dermatology.

[134]  C. Arteaga.  The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  S. Ylä-Herttuala,et al.  PDGF‐C and ‐D and their receptors PDGFR‐α and PDGFR‐β in atherosclerotic human arteries , 2009, European Journal of Clinical Investigation.

[136]  S. Kourembanas,et al.  Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. , 1998, American journal of respiratory cell and molecular biology.

[137]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[138]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[139]  H. Ghofrani,et al.  Updated classification and management of pulmonary hypertension , 2010, Heart.

[140]  P. Jones,et al.  Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension , 2005, Circulation.

[141]  Richard Clark,et al.  A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. , 2004, Blood.

[142]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[143]  M. Sasahara,et al.  Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. , 1996, Atherosclerosis.

[144]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[145]  H. Ben-bassat.  Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. , 2001, Current opinion in investigational drugs.

[146]  C. Dunwiddie,et al.  Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. , 1999, Circulation.

[147]  F. Moreau-Gaudry,et al.  The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells , 2009, Leukemia.

[148]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[149]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[150]  Gary R. Grotendorst,et al.  Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. , 1987, The New England journal of medicine.

[151]  A. Gabrielli,et al.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.

[152]  G. Sherbet,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER , 1985, The Lancet.

[153]  D. Matei,et al.  Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. , 2009, Gynecologic oncology.

[154]  G. Kouraklis,et al.  Expression of PDGF-A, TGFb and VCAM-1 during the Developmental Stages of Experimental Atherosclerosis , 2001, European Surgical Research.

[155]  E. Blomme,et al.  A Multitargeted Receptor Tyrosine Kinase Inhibitor, SU6668, Does Not Affect the Healing of Cutaneous Full-Thickness Incisional Wounds in SKH-1 Mice , 2006, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[156]  J. Johnston,et al.  Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[157]  A. Ribeiro,et al.  An evaluation of the cardiotoxicity of imatinib mesylate. , 2008, Leukemia research.

[158]  Yazawa,et al.  Serum concentrations of vascular endothelial growth factor in collagen diseases , 1998, The British journal of dermatology.

[159]  M. Mohammadi,et al.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. , 2007, Molecular cell.

[160]  W. Gerald,et al.  A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers , 2006, Investigational New Drugs.

[161]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .

[162]  P. Halloran,et al.  New developments in immunosuppressive therapy in renal transplantation , 2002, Expert opinion on biological therapy.

[163]  P. Jones,et al.  Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. , 1997, The American journal of pathology.

[164]  S. Wedgwood,et al.  Fibroblast Growth Factor-2 Expression Is Altered in Lambs With Increased Pulmonary Blood Flow and Pulmonary Hypertension , 2007, Pediatric Research.

[165]  K. Franchini,et al.  Focal adhesion kinase mediates MEF2 and c-Jun activation by stretch: role in the activation of the cardiac hypertrophic genetic program. , 2005, Cardiovascular research.

[166]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[167]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[168]  S. Ziegler,et al.  Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[169]  R. Hannan,et al.  Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. , 2004, Molecular endocrinology.

[170]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[171]  J. W. Miller.  Vascular endothelial growth factor and ocular neovascularization. , 1997, The American journal of pathology.

[172]  S. Erzurum,et al.  Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[173]  B. Jessen,et al.  Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[174]  J. O’Shea,et al.  Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.

[175]  G. Neufeld,et al.  Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. , 2000, The Journal of biological chemistry.

[176]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[177]  A. Levitzki,et al.  Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. , 1999, The Journal of pharmacology and experimental therapeutics.

[178]  M. Reidy,et al.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF , 1991, Science.

[179]  Peter Gierschik,et al.  Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration , 2000, Oncogene.

[180]  G. Semenza,et al.  Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.

[181]  D. Baran,et al.  A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. , 2008, Rheumatology.

[182]  H. Chan,et al.  Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. , 2004, Cellular and molecular life sciences : CMLS.

[183]  F. Russo,et al.  EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma , 1998 .

[184]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[185]  B. Reitz,et al.  Immunosuppression by the JAK3 Inhibitor CP-690,550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates , 2005, Transplantation.

[186]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[187]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[188]  R. Pazdur,et al.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[189]  M. Maitland,et al.  Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. , 2008, Physiological genomics.

[190]  Gary R. Grotendorst,et al.  Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity , 1986, Nature.

[191]  I. Fishbein,et al.  PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. , 1998, Circulation.

[192]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[193]  W. Stetler-Stevenson,et al.  Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. , 1997, Circulation.

[194]  M. Baccarani,et al.  Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy , 2009, Nature Clinical Practice Oncology.

[195]  B. Pluim,et al.  Left Ventricular Hypertrophy , 2020, Developments in Cardiovascular Medicine.

[196]  J. Berlin,et al.  A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas , 2008, Investigational new drugs.

[197]  M. Gordon.  Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma , 2009 .

[198]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[199]  M. Siddiqui,et al.  Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. , 2006, Vascular pharmacology.

[200]  M. Maitland,et al.  A Dosing/Cross‐Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension , 2010, Clinical pharmacology and therapeutics.

[201]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[202]  S. Sone,et al.  Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. , 2005, American journal of respiratory and critical care medicine.

[203]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[204]  A. Kastrati,et al.  A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. , 2005, Journal of the American College of Cardiology.

[205]  Y. Kurogi.  Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease , 2003, Medicinal research reviews.

[206]  C. Ruwhof,et al.  Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. , 2000, Cardiovascular research.

[207]  V. Gorgoulis,et al.  Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. , 1992, Anticancer research.

[208]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[209]  C. Heldin,et al.  INDUCTION OF B-TYPE RECEPTORS FOR PLATELET-DERIVED GROWTH FACTOR IN VASCULAR INFLAMMATION: POSSIBLE IMPLICATIONS FOR DEVELOPMENT OF VASCULAR PROLIFERATIVE LESIONS , 1988, The Lancet.

[210]  A. Nairn,et al.  Actions of Genistein on Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating , 1998, The Journal of general physiology.

[211]  A. Ziegler,et al.  Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension , 2005, Respiratory research.

[212]  M. Mendez,et al.  Carvedilol-induced antagonism of angiotensin II: focus on AT1 receptor-alpha1 adrenoceptor crosstalk , 2004 .

[213]  J. Penninger,et al.  Cardiac regulation by phosphoinositide 3-kinases and PTEN. , 2008, Cardiovascular research.

[214]  Sábata S Constancio,et al.  Focal Adhesion Kinase Is Activated and Mediates the Early Hypertrophic Response to Stretch in Cardiac Myocytes , 2003, Circulation research.

[215]  H. Farber,et al.  Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. , 2006, Annals of internal medicine.

[216]  W. Tilley,et al.  Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. , 1997, The Journal of urology.

[217]  W. Seeger,et al.  Imatinib for the treatment of pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[218]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[219]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[220]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[221]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[222]  M. Humbert,et al.  Reduced exercise capacity in a mouse model of asthma , 2006, Thorax.

[223]  Í. Lopes-Cendes,et al.  Shp2 Negatively Regulates Growth in Cardiomyocytes by Controlling Focal Adhesion Kinase/Src and mTOR Pathways , 2008, Circulation research.

[224]  R. Crystal,et al.  Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis. , 1990, The Journal of clinical investigation.

[225]  M. Rabinovitch,et al.  Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. , 1996, Circulation research.

[226]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[227]  E. Masuda,et al.  Novel Immunosuppression: R348, a JAK3- and Syk-Inhibitor Attenuates Acute Cardiac Allograft Rejection , 2008, Transplantation.

[228]  E. Nabel,et al.  Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. , 1993, The Journal of clinical investigation.

[229]  T. Brümmendorf,et al.  Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[230]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[231]  M. Humbert,et al.  Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[232]  P. Libby,et al.  Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. , 1988, The New England journal of medicine.

[233]  A. Levitzki,et al.  Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. , 1994, Science.

[234]  G. Neufeld,et al.  Neuropilin-2 and Neuropilin-1 Are Receptors for the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF) and of Placenta Growth Factor-2, but Only Neuropilin-2 Functions as a Receptor for the 145-Amino Acid Form of VEGF* , 2000, The Journal of Biological Chemistry.

[235]  G J Roth,et al.  Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis , 2007, European Respiratory Journal.

[236]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[237]  J. Knowles,et al.  Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. , 2005, American journal of respiratory cell and molecular biology.

[238]  C. Zielinski,et al.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[239]  S. Oparil,et al.  Fibroblast growth factor mediates hypoxia-induced endothelin-- a receptor expression in lung artery smooth muscle cells. , 2003, Journal of applied physiology.

[240]  E. Buchdunger,et al.  Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. , 1999, American journal of respiratory and critical care medicine.

[241]  Raed A Dweik,et al.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[242]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[243]  B. Barraclough,et al.  PARAQUAT POISONING , 1976, The Lancet.

[244]  K. Alitalo,et al.  Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors. , 1998, Development.

[245]  E. Raymond,et al.  Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. , 2009, The Lancet. Oncology.

[246]  N. Voelkel,et al.  Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[247]  Richard G. W. Anderson,et al.  Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFR beta). , 2005, The Journal of biological chemistry.